Abstract 336P
Background
Immune checkpoint inhibitor (ICI) plus Chemotherapy has now become the new standard treatment for non-small-cell lung cancer (NSCLC). However, little is known about comparison of ICI plus Chemotherapy and ICI monotherapy in the real world.
Methods
Patients with PD-L1-positive, advanced NSCLC treated with pembrolizumab plus chemotherapy (C group) or pembrolizumab monotherapy (M group) at Sendai Kousei Hospital between May 2015 to June 2019 were included in our study. C group received different treatments depending on histology: Patients with squamous NSCLC were received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]–paclitaxel plus pembrolizumab followed by pembrolizumab maintenance therapy. Patients with non-squamous NSCLC were received pemetrexed and a platinum-based drug plus pembrolizumab followed by pembrolizumab plus pemetrexed maintenance therapy. Two groups were evaluated with respect to adverse event (AE) profiles, objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).
Results
The following were observed: patient background (C group/ M group) number of cases 13/ 38 cases, median age 64/ 73 years old, male 76.9/71.1 %, Performance Status 0 or 1/ 2/ ≧3 (13/ 0/ 0) / (36/ 2/ 0), median observation period 5.1/ 7.4 months, development of AEs 100/ 84.2 %, development of immune-rerated AEs (irAEs) 61.5/ 84.2 %, development of irAEs ≥ grade 3 7.7/ 21.1 %. There was no significant difference in the ORR (38.5/ 55.2 %; p = 0.199) and DCR (100/89.5 %; p = 0.561) between two groups. Three months PFS were 100 % in combination group and 76.3 % in monotherapy group. Median PFS wasn’t significant different between the two groups (5.9/ 9.2 months; p = 0.193). PFS within 3 months of treatment start of C group tended to be better than M group.
Conclusions
Median PFS wasn’t significantly different between the two groups, probably due to the short observation period. PFS within 3 months of treatment start of C group tended to be better than M group. C group had more AEs than M group. However, the frequency of severe irAEs in C group was similar to M group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Sugawara: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squib; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Chugai Pharma; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Eli Lilly and Company; Honoraria (self): Novartis; Honoraria (self): Kyowa Hakko Kirin. Y. Toi: Honoraria (self): Ono Pharmaceutical; Honoraria (self): MSD; Honoraria (self): AstraZeneca. Y. Kawashima: Honoraria (self): Chugai Pharma. A. Nakamura: Honoraria (self): MSD; Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca. S. Yamanda: Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Taiho Pharmaceutical. Y. Kimura: Honoraria (self): Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract